No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in 1990 and based in Bengaluru, India, Strides Pharma Science Limited operates as an international pharmaceutical company, involved in the creation, production, and sale of a wide array of pharmaceutical products. Its operations span numerous global markets, including Africa, Australia, North America, Europe, Asia, and India, and are structured into two main divisions: Pharmaceutical and Biopharmaceutical. The company's portfolio encompasses a comprehensive selection of generic pharmaceuticals, offered in various dosage forms such as tablets, hard and soft gelatin capsules, sachets, liquids, nasal sprays, powders, solids, ointments, and creams. Additionally, Strides Pharma Science develops and markets branded generic products targeting chronic conditions across therapeutic areas like women's health, central nervous system disorders, cardiovascular diseases, diabetes, dermatology, and probiotics, under recognized brands including Renerve, Unibrol, Combiart, Duotab, and Vitafer. Its institutional business also provides essential medications for infectious diseases, such as anti-retrovirals, anti-malarials, anti-tuberculosis drugs, and Hepatitis treatments. A key collaboration with Orbicular Pharmaceutical Technologies Private Limited focuses on the joint development, manufacturing, and commercialization of nasal spray formulations. The company adopted its current name, Strides Pharma Science Limited, in July 2018, having previously been known as Strides Shasun Limited.
www.strides.comNo one on the platform currently holds STAR.BO.
No tracked institution reports a position in STAR.BO as of their last filing.
No one on the platform has traded STAR.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.3% | — | — | — | ||
| Rev. Growth % | 8.6% | 8.2% | ||||
| Profit Margin % | 11.4% | -0.7% | 1.2% | |||
| Free Cash Flow Margin % | 2.5% | 2.6% | -1.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $56.7B | +17.5% | $68.30 | $66.95–$69.75 | — | 2 |
| 2028 | $67.3B | +18.7% | $93.55 | $88.35–$98.75 | — | 2 |
| 2029 | $73.4B | +9.1% | $97.00 | $95.09–$99.06 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-07-29 | $10.80 | $10.83 | +0.3% |
| 2024-10-24 | $10.50 | $10.51 | +0.1% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| STAR.BOStrides Pharma Science Limited | $1152.50 | -2.81% | $105.9B | — |
| AARTIPHARM.BOAarti Pharmalabs Limited | $789.30 | -4.55% | $71.2B | — |
| AARTIPHARM.NSAarti Pharmalabs Limited | $789.45 | -4.53% | $71.6B | — |
| FDC.BOFDC Limited | $349.35 | +2.15% | $56.8B | — |
| FDC.NSFDC Limited |
| $349.65 |
| +2.40% |
| $56.9B |
| — |
| MARKSANS.BOMarksans Pharma Limited | $312.40 | -4.84% | $141.6B | — |
| MARKSANS.NSMarksans Pharma Limited | $312.85 | -5.02% | $141.8B | — |
Source: Financial Modeling Prep · peers by sector/industry